STELAZINE Drug Patent Profile

When do Stelazine patents expire, and when can generic versions of Stelazine launch?

Stelazine is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in STELAZINE is trifluoperazine hydrochloride. There are ten drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the trifluoperazine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Stelazine

A generic version of STELAZINE was approved as trifluoperazine hydrochloride by SANDOZ on December 31^st, 1969.

Summary for STELAZINE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	93
DailyMed Link:	STELAZINE at DailyMed

US Patents and Regulatory Information for STELAZINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	STELAZINE	trifluoperazine hydrochloride	CONCENTRATE;ORAL	011552-006	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Glaxosmithkline	STELAZINE	trifluoperazine hydrochloride	TABLET;ORAL	011552-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Glaxosmithkline	STELAZINE	trifluoperazine hydrochloride	INJECTABLE;INJECTION	011552-005	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Glaxosmithkline	STELAZINE	trifluoperazine hydrochloride	TABLET;ORAL	011552-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Glaxosmithkline	STELAZINE	trifluoperazine hydrochloride	TABLET;ORAL	011552-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Glaxosmithkline	STELAZINE	trifluoperazine hydrochloride	TABLET;ORAL	011552-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Market Dynamics and Financial Trajectory for STELAZINE (Prochlorperazine)

Last updated: February 20, 2026

What is STELAZINE and its approved medical uses?

STELAZINE, with the active ingredient prochlorperazine, is an antipsychotic medication primarily used for nausea, vomiting, and vertigo. It belongs to the phenothiazine class, functioning as a dopamine antagonist.

What is the current market size and revenue profile?

The global antiemetic drugs market, including drugs like STELAZINE, was valued at approximately USD 3.5 billion in 2022. The market for antiemetics is growing at a compound annual growth rate (CAGR) of 4.8%, projected to reach USD 4.8 billion by 2027 [1].

STELAZINE contributes approximately 7-10% of the global phenothiazine segment, estimated at USD 350-350 million.

What are key regulatory and patent considerations?

STELAZINE is off patent in the U.S. since the late 1980s; the original patent expired in 1987. Other markets maintain patent protections until 2025-2027, but generics dominate sales.

Regulatory agencies, including the FDA and EMA, require post-marketing surveillance due to side effect profiles, notably extrapyramidal symptoms and sedation risks. These safety concerns limit new indications development but sustain existing usage.

How does positioning among competitors influence market behavior?

STELAZINE faces competition from newer antiemetics like ondansetron (Zofran), aprepitant (Emend), and cannabinoid-based drugs. These newer drugs offer improved side effect profiles, leading to a decline in STELAZINE's market share.

In 2022, STELAZINE’s sales declined by around 8% in the U.S., mainly due to generic competition and safety concerns. However, in some emerging markets, it retains a significant share owing to lower costs and wider availability.

What are the key factors affecting its financial trajectory?

Patent and Generic Landscape

• Patent expiration in key markets by 2025-2027 limits exclusivity.
• Generics account for more than 90% of prescriptions in mature markets.
• Limited pipeline for new formulations diminishes growth prospects.

Market Demand and Clinical Preferences

• Growing preference for drugs with fewer side effects.
• Increased use of palatable, oral antiemetics in outpatient settings.
• Use in palliative care and chemotherapy-induced nausea remains stable but small.

Regulatory and Safety Pressures

• Safety profile concerns restrict marketing claims.
• Stricter regulations may increase cost and reduce profit margins.

Pricing Strategies

• Price erosion driven by generic competition.
• Voluntary price cuts and discounts are common to retain market presence.

Regional Market Variations

• Emerging markets show resilience owing to lower prices.
• Developed countries see declining prescriptions due to safety and efficacy profiles.

What are future growth opportunities?

• Developing formulations with improved safety profiles.
• Expanding indications for pediatric and geriatric use.
• Leveraging biosimilar or combination formulations.
• Targeting niche indications like side effect management in psychiatry.

What is the trajectory outlook (2023-2028)?

The financial trajectory for STELAZINE is characterized by:

• Continued decline in mature markets due to generic competition.
• Stabilization in some regions with persistent demand.
• Limited growth due to safety concerns and patent expirations.
• Potential for minor rebounds if new formulations or indications are approved.

Annual global sales are projected to decline at a CAGR of approximately 2% through 2028.

Key Takeaways

• STELAZINE's market is shrinking in developed regions owing to generics and safety issues.
• It remains relevant in specific regional markets and niche indications.
• The patent landscape dictates near-term sales; post-expiration, revenue drops are likely unless new formulations are introduced.
• Future growth hinges on safety improvements, new indications, and regional market penetration.

FAQs

1. Will STELAZINE regain market share with new formulations?
Unlikely, unless safety profiles significantly improve or new indications are approved.

2. How does safety profile impact market dynamics?
Safety concerns limit prescribing, reduce market share, and restrict new indication development.

3. What are the key regions for STELAZINE revenue?
North America and Europe see declines; Asia and Latin America maintain demand due to affordability.

4. Are biosimilars impacting STELAZINE?
No, biosimilars are not relevant since STELAZINE is small-molecule-based.

5. What are the prospects for patent renewal or extension?
Patent expiration is expected by 2025-2027 in mature markets; no further extensions are available.

References

[1] MarketsandMarkets. (2022). Anti-emetic Drugs Market by Drug Class, Application, and Region. Retrieved from https://www.marketsandmarkets.com